2025 Financial Results Investor Presentation
Released
Released
Announcement PDF
ASX:TTX
Material science for safer,
faster and more precise
medicine
#anchoredbyscience
Disclaimer
IMPORTANT INFORMATION & DISCLAIMER
>
USE OF THIS DOCUMENT
You must read the following notices before reading or making any use of this document or any information contained in this document. By continuing to read, use or otherwise act on this document, you agree to be bound by the following terms and conditions, including any
modifications to them, and make or give the acknowledgements, representations or warranties (as applicable). This presentation is provided for information purposes only. The information in this presentation is in a summary form, does not purport to be complete and is not
intended to be relied upon as advice to investors or other persons. The information contained in this presentation was prepared by Tetratherix Limited ACN 607 771 077 (Tetratherix) as of its date, and remains subject to change without notice. This presentation has been
provided to you solely for the purpose of giving you background information about Tetratherix.
FORWARD-LOOKING STATEMENTS
This presentation may include forward looking statements. Such statements can generally be identified by the use of words such as 'may', 'will', 'expect', 'intend’, 'plan', 'estimate', 'anticipate', 'believe', 'continue', 'objectives', 'outlook', 'guidance‘, ‘forecast’ and similar
expressions. Indications of plans, strategies, management objectives, revenue and financial performance are also forward-looking statements. Such statements are not guarantees of future performance, and involve known and unknown risks, uncertainties, significant items
of subjective judgement, assumptions (including in relation to future events that may or may not eventuate), contingencies and other factors, many of which are outside the control of Tetratherix. No independent third party has reviewed the reasonableness of any such
statements or assumptions. No representation is made or will be made that any forward-looking statements will be achieved or will prove to be correct. Actual results, performance, operations or achievements may vary materially from any forward-looking statements.
Circumstances may change and the contents of this presentation may become outdated as a result. Readers are cautioned not to place undue reliance on forward looking statements. Except as required by law, Tetratherix assumes no obligation to release updates or
revisions to forward looking statements to reflect any changes. You should form your own views as to these matters and any assumptions on which such statements are based and not place reliance on such statements. No representation or warranty, expressed or implied,
is made as to the accuracy, reliability, adequacy or completeness of the information contained in this presentation. To the maximum extent permitted by law, Tetratherix excludes and disclaims all liability, including (without limitation) any liability for fraud or negligence, for any
expenses, losses, damages or costs incurred either as a result of the information in this presentation being inaccurate or incomplete in any way for any reason, or otherwise arising in connection with this presentation.
PAST PERFORMANCE AND RISKS
Past performance information given in this presentation is given for illustrative purposes only and should not be relied upon as (and is not) an indication of future performance. An investment in Tetratherix is subject to known and unknown risks, some of which are beyond the
control of Tetratherix, including factors and risks specific to the industry in which it operates as well as general economic conditions, prevailing exchange rates and interest rates and conditions in the financial markets. Tetratherix does not guarantee any particular rate of
return on its performance nor does it guarantee any particular tax treatment. Prospective investors should make their own enquiries and investigations regarding all information in this presentation, including the assumptions, uncertainties and contingencies which may affect
future operations and the impact that different future outcomes may have on Tetratherix.
NO OFFER, INVITATION OR ADVICE
This presentation is not, and is not intended to constitute, financial advice, or an offer or an invitation, solicitation or recommendation to acquire or sell Tetratherix shares or any other financial products in any jurisdiction and is not a prospectus, product disclosure statement,
disclosure document or other offering document under Australian law or any other law. This presentation does not form the basis of any contract or commitment to sell or apply for securities in Tetratherix or any of its subsidiaries. It is for information purposes only. Tetratherix
does not warrant or represent that the information in this presentation is free from errors, omissions or misrepresentations or is suitable for your intended use. The information contained in this presentation has been prepared without taking account of any person’s
investment objectives, financial situation or particular needs and nothing contained in this presentation constitutes investment, legal, tax or other advice. The information provided in this presentation may not be suitable for your specific needs and should not be relied upon by
you in substitution of you obtaining independent advice. Subject to any terms implied by law and which cannot be excluded, Tetratherix accepts no responsibility for any loss, damage, cost or expense (whether direct, or indirect, consequential, exceptional or special
damages including but not limited to loss of revenue, profits, time, goodwill, data, anticipated savings, opportunity, business reputation, future reputation, production or profit, any delay costs, economic loss or damage) incurred by you as a result of any error, omission or
misrepresentation in this presentation.
UNAUDITED INFORMATION
All forward-looking figures and proforma statements in this presentation are unaudited. Certain figures may be subject to rounding differences. All market share information in this presentation is based on management estimates having regard to internally available
information unless otherwise stated.
PRESENTATION OF INFORMATION
All currency amounts in this presentation are in Australian dollars unless otherwise stated.
I
#anchoredbyscience
Team
Will Knox
Dr Ali Fathi
CEO
FOUNDER & CTO
Will comes from a long history of medical and biological
technology development. Prior to Tetratherix, Will has worked for
small and large businesses in Australia and offshore such as
Cochlear, Medtronic and LifeHealthcare. Will has also established
his own company in regenerative medicine that was acquired in
2017 by Australian private equity. Combining both the clinical and
commercial worlds, Will brings a unique and well respected
combination of skillsets to our business.
Ali is a world-renowned researcher and inventor of Tetramatrix
and has continued the development of the technology using
his technical and entrepreneurial vision. Ali is a globally
respected chemical engineer and is one of Australia’s most
published young researchers. Using his unique approach to
engineering science-based solutions for the real world, Ali has
created a technology that has been deliberately considered
from start to finish.
Cherie Beach
Terence Abrams
CFO
FOUNDER & COO
Cherie is the epitome of a strategic CFO and brings many years
of experience within healthcare and medical technology. Cherie
was most recently a senior finance leader at Cochlear and
Johnson&Johnson, and has a long history of strategic financial
stewardship in our industry. Cherie has an unparalleled
combination of leading global financial process with fast-growing
innovative thinking - a combination that allows us to grow rapidly
while ensuring commercial stability & reliability.
Terence (Tez) is an extremely experienced chemical engineer
who has over a decade of experience in bespoke compounding,
polymer production & infrastructure design for complex
biomaterials. Tez is the engine that drives the unique
differentiation behind our advanced manufacturing. Adopting
critical thinking and first principles, Tez is a pragmatic problem
solver who combines chemistry, quality systems and commercial
objectives - a skillset that is standalone in our industry.
The executive leadership team are supported by a deep bench of scientific & commercial
advisors who are highly regarded leaders in their respective fields
1
#anchoredbyscience
Introduction
An operational moat with IP Leadership built on a global R&D infrastructure. This sets us apart.
1 Lean & rapid R&D
Multiple independent research partnerships help us
develop technologies faster and cheaper than our peers
2 Robust Quality System
We built a quality system from the ground up
deliberately from day 1 - not just a science experiment
3 Strategic Patent Library
Our approach to patent coverage is
optimised for future growth
38%
R&D*
Supported by complete IP coverage
Patent stack with 36 granted patents from 9 families of patent,
extending to 2044 & beyond and fully owned by Tetratherix
2
Total Underlying
Expenditure
*R&D includes specific projects, directly attributable staff,
laboratory costs, trademarks and patents
#anchoredbyscience
Introduction
Tetramatrix™ - A proven material platform that provides differentiation across multiple indications
Clinically
Modular
An entirely new range of
chemical entities that are
built on a platform with
deliberate conviction
Minimally
Invasive
Low cost & scaled
manufacturing
3
#anchoredbyscience
Introduction
Tetramatrix™ platform technology is the world’s first biostealth fluid matrix
Modular
A biomaterial platform built with unique polymer programming akin to “medical Lego ” to
form implantable products to solve a wide range of clinical problems. The platform has built
products for 7 anatomical sites with 3 chemical entities derived from the core technology.
Biomimetic
Safe
4
The matrix has similar water content and mechanical properties
to natural tissue, and therefore is impervious to the body, helping
heal injuries or physically manipulating the body during surgical
interventions.
Due to the unique polymer programming of the material, once the matrix
serves its purpose, the material gradually and safely bioresorbs in the body
with no impact locally or systemically. Biocompatibility data from multiple
clinical trials show no impact to internal organs or blood markers.
Human Histological Evaluation
Inflammatory Fibrovascular (IFV)
Tissue ingrowth
Opaque
Structure
Transparent
5 minutes
Stability
12 weeks
Eye tissue
Biomechanics
Long-bone
Treated with
our platform
A decade of polymer programming has led to an ideal consistency & physical performance.
The material is an injectable fluid to avoid causing damage to the body during its application.
Using physiological temperature, material transitions into a 3D matrix.
Standard of
care
Intelligent
Preclinical studies (equivalent to 5 litre product administration)
No effects on blood markers for internal functions of
liver, kidney and spleen
Fully resorbed and excreted from the body
#anchoredbyscience
Introduction
Why does the world need Tetratherix?
The evolving dynamics of the global healthcare system is demanding innovative and cost-effective biomaterials
Trends in healthcare delivery
5
How does Tetramatrix address the problem?
Rising patient expectations
Minimally invasive delivery
Patients are demanding increasingly higher quality of care, with a
particular focus on reducing recovery times and lowering risk of
complications (e.g. infection, blood loss, pain) - which is also a driver
of increasing healthcare costs for patients and payers.
Safe, biocompatible and bioresorbable
Water-based solution injected through fine gauge needle
No foreign body reaction upon application
Need for cost-effective, decentralised care
Low cost, scalable production
Increasing global healthcare spending and demand for healthcare
services is necessitating investment in cost-effective tools and
treatments, including those that can be delivered outside a traditional
hospital setting, to minimise burden on the healthcare system
Seamlessly integrated into existing workflows
Non-labour intensive, low cost and readily available materials
Delivered via needle with no additional equipment required
#anchoredbyscience
Franchises
15 years and 14 programs have helped define 5
initial products on the Tetramatrix™ platform
technology
An initial addressable
combined market of
$USD6.8B
6
$6.8B
#anchoredbyscience
Franchises
Derived products from the Tetramatrix™ platform technology span 3 large
franchises and significant near-term commercial opportunities
Bone Regeneration
Flowable bone graft
extender for orthopaedic
applications
Bone graft extender for
dental surgeries
Tissue Spacing
Spacer during
cataract surgeries
Prostate Spacer for
radiation therapy
Tissue Healing
Intraoperative solution to reduce scar
formation after surgeries
Same core
technology, same
material and
interchangeable
dataset
7
95%
#anchoredbyscience
Commercial model
TM
Different clinical needs. Different market segments. Single Tetramatrix
platform technology.
Think of us like a software platform business...
Bone
Regeneration
Tissue Spacing
The Tetramatrix biomaterial is our core ‘platform’ technology. We have
completed the foundational safety, efficacy and manufacturing work which is
transferable across different clinical applications of the platform.
We will license the IP in a specific field to a leader in the segment. These
partners complete the “final 20%” to turn the application into a clinical product.
We will then manufacture the product and supply at attractive unit economics to
our industry leading partners who distribute it though their sales channels.
+ multiple other blue
sky opportunities
We will enjoy periodic milestone payments as well as a steady flow of income
from product supply - a dual revenue source brings the best of both worlds.
Tissue
Healing
Same core technology,
same material and
interchangeable dataset
8
Licensing &
Milestone
Payments
1
2
Supply of
product at
scale
#anchoredbyscience
Commercial model
A partnership model built on long term trust & deliberate pathway to market
Our Partnership model
STAGE 1
Proof of Concept
Tetratherix uses
foundational Tetramatrix™
data to conduct proof-ofconcept and pilot trials,
aligning endpoints and
assessments with partners
throughout the process
9
A true ‘win-win’ for TTX and its partners
STAGE 2
Transition to Market
STAGE 3
In Market
PARTNER
PARTNER
Tetratherix and its partner
co-develop regulatory,
reimbursement and launch
strategies. Alignment on
product form, branding and
short-term manufacturing
underpins regulatory
submission and market
entry
With medtech launch
experience, the partner
will design a roll-out
strategy focused on key
regions and clinical
marketing to ensure a
steady, sustainable
market entry
Staged partnership built on tight collaboration
that will limit risk and build long-term
sustainability
Reducing Risk
with Diversified
Franchises
By having multiple shots on goal across a range of market and
partner opportunities, we reduce the regulatory, technical and
commercial risk inherent to our peers in the medical
technology industry.
Faster Path to
Free Cash
Flow for TTX
We deliberately utilise our partners’ global infrastructure for
sales and distribution. This creates a capital-light cost structure
upon which sits rapidly compounding revenue.
Enabling CostEffective R&D for
Partners
Early integration of the TetramatrixTM platform technology into
partners’ internal development programs reduces their R&D
inertia and reliance on late-stage M&A to meet their
customers’ needs.
#anchoredbyscience
Commercial model
A capital light model with compounding revenue
Importantly, we operate in unison with our partners. Our high margin revenue
compounds over time by adding new partnerships and launching new products.
Income
While we build our own production and R&D infrastructure, we avoid committing
capital on establishing multiple sales & distribution networks by utilising the
capabilities of our partners’ established teams.
Similar to a ‘build-to-buy’ model, we partner differently to, and at earlier stages than,
traditional medtech companies. Therefore, our return profile is different and not built
on expectations of an eventual acquisition.
Rod Drury
Xero Founder & Tetratherix Investor
10
Proof of Concept
Clinical
Validation
Regulatory
Approval
Go-to-Market
Cost
"Tetratherix is software platform thinking applied to
the vast opportunity for smart medicines. I’m excited
about the many applications that can be delivered
over time and the impact they will have to millions of
people.”
Design
Plateaued Cost
In TTX Model
Avoided Sales &
Marketing Cost by
using partners’ inmarket infrastructure
#anchoredbyscience
Commercialisation
Strategic Commercialisation built on decades of global launches. It’s in our DNA.
1
Commercial Viability Assessment as a first step
We determine commercial reality of the program including unit economics,
reimbursement, ASC vs Hospital program as well as gross margin splits for all
stakeholders. Not simply a great science experiment.
2
Partnership Confirmation after many years of diligence
We ensure our partner of choice is motivated, aligned and the right choice on
the ground. Focus of strategic portfolio not only now but over the next 5+
years. This can take time but its worth it.
3
US Seeding Program following 510k clearance
Our products have to introduced into the market effectively to ensure sustainable and effective
long term growth. This includes careful selection of a small number of US tier 1 key opinion
leaders (KOLs) who provide clinical feedback and controlled usage in early stages of US launch.
4
US Market Expansion (P2P)
Following a 1-2 year seeding period, we work with our selected partner to expand into
tier 2 KOLs via careful peer-to-peer education & marketing with inclusion of messaging
tips and advice from seeding KOLs. Organic US growth follows.
5
Geographical Expansion on the back of refining innovation uptake
With US tier 1 and tier 2 usage under our belts, we utilise this loyal and leading group of
physicians to collect US data for CE mark, Asia and Sth American expansion - with
these markets adopting our seeding approach where suitable.
11
#anchoredbyscience
Unit Economics
Not simply a science experiment. TetramatrixTM provides real world economics.
Bone
Regeneration
Tissue Spacing
Tissue Healing
TAM
US$3.4bn
US$1.3bn
US$2.1bn
Payer
Patient outof-pocket
Reimbursed
(US)
Patient outof-pocket
Expected GM1 for
Partner
70-80%
~80-90%
~70-80%
Expected GM for
TTX
60-70%
~75-85%
~60-70%
We verify the final end
user pricing and the gross
margin targets for our
strategic partners before
progressing
1. Weighted Blended Gross Margin
12
#anchoredbyscience
Manufacturing
Advanced manufacturing and operations
We have established advanced manufacturing in Sydney. To meet growing demand, a new
lease agreement has been executed and the new facility is planned to be commissioned in
2026, with a modular design to allow us to quickly scale as needed.
Our manufacturing process is:
Manufacturing POD
Highly Scalable with supply chain security
Our manufacturing process is design in a ‘POD’ framework whereby every POD can operate independently
The POD has a foot print of 200 sqm, and can be replicated multiple times without our facility floorspace
Allows multiple X increases in the production capacity in a fast and controlled manner
De-risked
We have previously increased our production yield per batch from laboratory scale (10 g per batch) to a commercial
scale (1.2kg) through multiple cycles of process optimisation and scale up
The production process is not labour-intensive and requires only off-the-shelf equipment
All raw materials are catalogue products and easily accessible from multiple suppliers, de-risking any supply chain risk
A new, larger site in Alexandria, Sydney has been identified with the lease now executed and signed
13
#anchoredbyscience
Subsequent Event
Industry Growth Program (IGP) - $3.3m non-dilutive grant from the Australian Government
This goes beyond the science. TTX has defined the program, modelling attractive
unit economics for all parties in the value-chain and focused on
commercialisation of Tetramatrix.
14
$3.3m IGP grant is an upside to TTX Use of Funds.
Co-funding will enable further investment in additional R&D programs and
advanced manufacturing capabilities
Commercialisation
via Advanced
Manufacturing
Bone Regeneration
(Dental
Application)
Pipeline
Product
Development
Objective:
Inventory build-up for our bone
regeneration program.
Objective:
Licenced Tetramatrix in dental
applications to Henry Schein
Objective:
Completion of an additional clinical
trial under Tissue Healing Franchise
$7.4m total project cost already budgeted in
TTX’s use of funds, across FY26 and FY27
Project Outcomes:
Advanced manufacturing
capability for commercial
scale production
Proprietary polymer and
final product output
Project Outcomes:
510(k) FDA clearance (Lyc
product code for dental
applications)
First commercial sales of
Tegenix to Henry Schein
Project Outcomes:
Enable TTX to licence the
technology to market
leaders in sports medicine
IGP grant
$3.3m
TTX funded
$4.1m
TTX to provide quarterly reporting on progress towards key milestones.
Each quarterly contribution is payable by the government in advance and the total
annual contribution is capped at the approved amount.
#anchoredbyscience
Financials
Our financial position reflects a strong capital structure to support continued investment in R&D and
upscale of our manufacturing capability for commercialisation readiness
Underlying* loss +78% unfavourable vs. FY24 driven by higher R&D & headcount expansion
$AUD
Million
(3,912)
Reported Loss
After Tax
Despite increased headcount & listed
company costs in FY25 our capital
light model remains efficient
Current Assets
One-off Expenses (1)
Reported Loss
1% Improvement
Net Fair Value
Loss (non-cash)
Property, plant
and equipment
Current Liabilities
Underlying (1) Loss
IPO Cost
(P&L)
FY24
$0.237
Underlying Loss
After Tax
FY25
$0.234
($4.6m)
($9.4 m)
Strong financial position with $29.3m
cash on hand & zero financing debt
Working
Capital $28.4m
$1.3 m
$3.6m
(1) Underlying removes one off expenses
Transaction
costs (equity)
$AUD
Million
Underlying (1) Overheads
(ex R&D investment) per employee
15
#anchoredbyscience
Financials
Our financial position reflects a strong capital structure to support continued investment in R&D and
upscale of our manufacturing capability for commercialisation readiness
Total Income + 32% vs. FY24 to support R&D and advanced manufacturing
Continued investment in R&D to fuel growth
38% of total underlying opex, +24% vs FY24
32%
Increase
INCOME
$AUD
Million
FY24
$0.86 m
FY25
$1.14 m
Pipeline
($0.4m)
38%
R&D
Bone
Regeneration
($1.2m)
Tissue Healing
($0.6m)
FY25
$AUD Million
Total Underlying (1) Expenditure
(1) Underlying removes one off expenses
16
#anchoredbyscience
Near Term Milestones
Relentless execution with regular newsflow in first 12 months post-listing
Bone
Regeneration
Henry Schein Supply and
Licensing Agreement
Execution
DENTAL
Master Partnership
Agreement
Execution
ORTHOPAEDIC
Data Read-out from the
FDA study
FDA Submission
FDA
Clearance
Supply and Licensing
Agreement Execution
FDA Submission
FDA
Clearance
Tissue Spacing
ONCOLOGY
OPHTHALMIC
BioOptix
Licensing
Agreement
Strategic Global
Partnership
SURGICAL
SITE MGMT
Cohort 2
Commenced
Year 1 Follow up
for Cohort 1 results
published
Tissue Healing
FY2026
17
Tutelix First In
Human Cohort 1
Read-out
FDA Pre-submission/
Regulatory Pathway
Defined
Quality Agreement
Execution
US/AU
Capital Raise
US / AU
Capital Raise
Primary Endpoint Cohort 2
Tutelix Primary End
Point for Cohort 2
Preclinical Data
Read-out
FDA Pre-submission
& Regulatory Pathway
US Clinical Trial
Initiation
FDA Pre-submission &
Regulatory Pathway
TetraDerm Cohort
3 Initiation
(Major Surgeries)
FY2027
#anchoredbyscience
Copyright Tetratherix Ltd. 2025 “Tetratherix”
Share your feedback
Discover